Share Twitter LinkedIn Facebook Email Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Read here: https://meetinglibrary.asco.org/record/185846/abstract Advertisement
Understanding and Managing BPDCN: Insights from Priyanka Meta’s Conference Presentation Other 2 Mins Read
Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission [ASH 2023] Other 1 Min Read